-
About Createrna
An Innovative Company Driven by R&D Pipeline and Platform
Createrna is an innovative drug research and development company in the clinical stage. Adhering to the dual-driven strategy of simultaneous development of the R&D pipeline and platform, the company has built a new drug research and development system covering the whole process from proof-of-concept, candidate compound screening, preclinical druggability development to clinical research.
-
240+
Employee
-
180+
Researchers
-
15+
Projects
-
25+
Pipelines
-
200+
Patents
-
300+
Partners
The Global Distribution
-
Shanghai R&D Center
Building A, 3333 Shenjiang Road, Pudong New Area, Shanghai, China
The R&D branch center consists of project management department, pharmacy department, Pharmacology Department and Intellectual Property Department, which is responsible for providing R&D services such as proof of concept, in vitro and in vivo model construction and drug synthesis for clinical projects.
-
International Center
Maryland, USA
Business development and FDA application for customers and investors of pharmaceutical companies in the United States and Europe, connecting research centers of the company with foreign pharmaceutical companies and scientific research institutions.
-
Wuhan R&D Center
Wuhan, China Wuhan High-tech Zone National biological Industry Base
The integrated center for functional operations management and preclinical research and development. There are project management department, pharmaceutical department, Pharmacology Department and intellectual Property Department, which provide research and development services include POC, in vitro and in vivo model construction and drug synthesis for clinical projects.
-
Translational Medicine Center
Wuhan, China Wuhan High-tech Zone National biological Industry Base
Responsible for exploring clinical needs by integrating external expert resources, determining the relationship between targets and disease development, exploring and verifying the mechanism of action of drugs, discovering and selecting biomarkers, exploring product differentiation advantages, participating in the evaluation of clinical research strategies, and helping to improve the efficiency and success rate of new drug research and development.
-
Clinical Medical Center
New Changjiang Plaza, 2 Youyi Avenue, Wuchang District, Wuhan City, China
Led the company's clinical trials of innovative drugs, and was responsible for the clinical safety and efficacy studies, clinical pharmacology studies, compliance management of trial execution, clinical transfer and CRO, and construction of clinical base resources from before and after IND to market.
-
Shanghai R&D Center
Building A, 3333 Shenjiang Road, Pudong New Area, Shanghai, China
The R&D branch center consists of project management department, pharmacy department, Pharmacology Department and Intellectual Property Department, which is responsible for providing R&D services such as proof of concept, in vitro and in vivo model construction and drug synthesis for clinical projects.
-
International Center
Maryland, USA
Business development and FDA application for customers and investors of pharmaceutical companies in the United States and Europe, connecting research centers of the company with foreign pharmaceutical companies and scientific research institutions.
-
Wuhan R&D Center
Wuhan, China Wuhan High-tech Zone National biological Industry Base
The integrated center for functional operations management and preclinical research and development. There are project management department, pharmaceutical department, Pharmacology Department and intellectual Property Department, which provide research and development services include POC, in vitro and in vivo model construction and drug synthesis for clinical projects.
-
Translational Medicine Center
Wuhan, China Wuhan High-tech Zone National biological Industry Base
Responsible for exploring clinical needs by integrating external expert resources, determining the relationship between targets and disease development, exploring and verifying the mechanism of action of drugs, discovering and selecting biomarkers, exploring product differentiation advantages, participating in the evaluation of clinical research strategies, and helping to improve the efficiency and success rate of new drug research and development.
Development Course
-
In May 2013
Createrna Development Co., Ltd. was established
-
In March 2015
Early activity screening evaluation model construction team was established;
In vivo model building platform is completed
-
In August 2018
A medical information platform has been established;
Obtained the national intellectual Property Management system certification
-
In September 2021
Awarded as excellent high-tech enterprise;
PHN treatment MY008211A tablet entered Phase I clinical trials;
The IBD treatment MY009212A tablet entered Phase I clinical trials;
Dr. Yaning Wang has been appointed CEO of Createrna
-
In October 2021
Chronic cough treatment QR052107B tablets entered Phase I clinical trials;
Rheumatoid arthritis treatment MY004567 entered Phase I clinical trials
-
In March 2022
P2X3 receptor antagonist enters Phase II clinical trials;
Chronic pain treatment QR0606127 capsules entered Phase I clinical trials;
A clinical medical center has been established
-
In April 2022
Dr. Jing Zhang has been appointed CMO of Createrna
-
In April 2023
A research center for translational medicine has been established
-
2013
-
2015
-
2018
-
2021
-
2021
-
2022
-
2022
-
2023
Honors and Qualifications
-
National High-Tech Enterprise
-
National Torch Plan Key High-Tech Enterprise
-
National Postdoctoral Research Station
-
National and Local Joint Engineering Research Center
